Cedrik M. Britten

Directeur Technique/Scientifique/R&D chez IMMATICS N.V.

Fortune : 2 M $ au 30/04/2024

49 ans

Health Technology

Consumer Services

Postes actifs de Cedrik M. Britten

Sociétés	Poste	Début	Fin
IMMATICS N.V.	Directeur Technique/Scientifique/R&D	01/06/2020	-
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Directeur Technique/Scientifique/R&D	01/06/2020	-

Sociétés	Poste	Début	Fin
GSK PLC	Corporate Officer/Principal	01/02/2015	01/05/2020
BioNTech RNA Pharmaceuticals GmbH BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The company is based in Mainz, Germany.	Directeur Technique/Scientifique/R&D	01/06/2010	01/01/2015

The Johannes Gutenberg University of Mainz

Doctorate Degree

Internationale

Allemagne	5
Royaume-Uni	2

Opérationnelle

Chief Tech/Sci/R&D Officer	3
Corporate Officer/Principal	1
Doctorate Degree	1

Sectorielle

Health Technology	5
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
GSK PLC	Health Technology
IMMATICS N.V.	Health Technology

Entreprise privées	2
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Health Technology
BioNTech RNA Pharmaceuticals GmbH BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The company is based in Mainz, Germany.	Health Technology

Entreprise privées

Health Technology